Semaglutide Weight Loss: What Clinical Data Shows

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Clinical trials demonstrate that semaglutide can help reduce body weight by approximately 10–22% over 68 weeks, with most significant loss occurring in the first 6 months. Individual results vary widely based on dose, adherence, lifestyle factors, and underlying metabolic characteristics.

Why this matters: weight-loss expectations should be grounded in clinical evidence, not marketing claims. PlexusDx supports precision-wellness by helping patients understand their metabolic starting point and genetic context before starting treatment, enabling more realistic goal-setting with their healthcare provider.

Clinical Trial Data on Semaglutide Weight Loss

The STEP trials (Semaglutide Treatment Effect in People with Obesity) remain the gold standard for understanding semaglutide's weight-loss potential in non-diabetic adults. Participants receiving the highest dose (2.4 mg weekly) achieved mean weight loss of 14.9% from baseline over 68 weeks, compared to 2.4% in the placebo group.

Lower doses produced proportionally lower results. The 1.7 mg dose showed mean weight loss of approximately 11% at 68 weeks. In the SUSTAIN trials (diabetes populations), weight reductions ranged from 3.7% to 6.5% depending on baseline glycemic control and concurrent medication use.

Why Individual Results Vary So Much

Genetics, metabolic rate, gut microbiota composition, baseline insulin sensitivity, and lifestyle adherence all influence how much weight someone loses on semaglutide. Two patients on identical doses may experience 5% weight loss and 15% weight loss respectively due to these individual factors.

Factor Influencing Response	Clinical Relevance
GLP-1 receptor variants (rs6923761)	Genetic variation in GLP-1R expression may influence satiety signaling and appetite suppression intensity
Baseline metabolic rate	Higher baseline metabolism may require higher doses or longer duration to see equivalent percentage weight loss
Insulin resistance severity	Elevated fasting insulin may predict better early response; normal insulin may show delayed response
Dietary adherence and protein intake	Semaglutide effect is augmented by adequate protein intake; low-protein diets show suboptimal weight loss
Exercise and activity level	Sedentary baseline predicts larger absolute weight loss; already-active patients see smaller percentage reductions
Gastric emptying rate	Individual variation in stomach function influences nausea tolerance and dose escalation speed

The Role of Genetic Predispositions in Appetite Regulation

Variants in genes controlling appetite, energy expenditure, and fat storage—such as FTO rs9939609 and MC4R rs17782313—can help contextualize baseline metabolic risk and predict how responsive someone might be to GLP-1 medication. These variants reveal predispositions in peptide pathways, not fixed outcomes.

Understanding your genetic context supports a more informed conversation with your provider about realistic timelines, expected weight-loss range, and whether dose adjustments or complementary lifestyle interventions might be beneficial. This is why biomarker-informed treatment planning differs from one-size-fits-all protocols.

Who Achieves the Most Weight Loss: Provider Evaluation Matters

Clinical evidence suggests that patients with baseline BMI ≥30, no prior GLP-1 exposure, good medication adherence, and willingness to modify diet typically experience the largest absolute and percentage weight loss. However, these are trends, not guarantees—individual response remains unpredictable without baseline biomarker assessment.

Your provider should evaluate your medical history, metabolic markers (fasting glucose, insulin, lipids), current medications, and any contraindications before initiating treatment. This clinical context helps set realistic expectations and identify whether compounded semaglutide, oral options, or alternative approaches are most appropriate for your situation.

How PlexusDx Supports a More Personalized Approach

The PlexusDx Precision Peptide Genetic Test examines key variants in GLP-1R, GIPR, FTO, and MC4R pathways to reveal your genetic predispositions toward appetite regulation, energy expenditure, and metabolic response patterns. This information may help provide context for realistic weight-loss expectations and inform dose-escalation planning with your provider.

Genetic predispositions are NOT predictors of exact medication response or guaranteed outcomes. Rather, they reveal biological patterns that, when combined with clinical markers (insulin levels, metabolic rate, lifestyle factors), support a more nuanced conversation about treatment optimization. Your genes influence the probability of response, not the certainty.

Interpreting your genetic results alongside baseline metabolic labs and lifestyle history can help you and your provider move beyond one-size-fits-all protocols and toward personalized treatment planning. This approach should always be conducted with qualified healthcare provider guidance.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.